BioGend Therapeutics Co., Ltd. is applying for listing on TPEx . At the time of application, the company has capital in the amount of NT$920,000 thousand, its chairman is Te Li Chen, and its recommending securities firms include Yuanta Securities, Reliance Securities, Capital Securities and Cathay Securities.
Revenue, net loss after tax and loss per share of the applicant reports for FY 2019 were NT$1,461 thousand, NT$162,903 thousand, and NT$2.01 respectively. Revenue, net loss after tax and loss per share of the applicant reports for first half of FY 2020 were NT$485 thousand, NT$70,113 thousand, and NT$0.85 respectively.
|